Implications of applied research for prognosis and therapy of breast cancer

被引：5

作者：

Barginear, M. F. ^{[1
]}

Bradley, T. ^{[1
]}

Shapira, I. ^{[1
]}

Budman, D. R. ^{[1
]}

机构：

[1] CUNY, Sch Med, N Shore Univ Hosp, Don Monti Div Med Oncol Div Hematol, New York, NY USA

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2008年 / 65卷 / 03期

关键词：

breast cancer; molecular profiling; gene expression profiles;

D O I：

10.1016/j.critrevonc.2007.11.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer is the one of leading causes of cancer-related deaths in women within economically developed regions of the world. The heterogeneity of the natural history of breast cancer complicates patient management in that there is tremendous variability in response to treatment and for survival. More recently, several biomarkers (hormone receptor status and HER2 expression) have been added to the risk evaluation and therapeutic assessments. Evolving knowledge of molecular biology and newer techniques, such as genomics and proteomics, offer the potential to better define the biologic nature of the disease process, both for risk and therapy. This review discusses classical as well as new prognostic and predictive techniques. These are leading to a paradigm shift from empirical treatment to an individually tailored approach, which may soon become a realistic option for patients, based on specific molecular profiles. (c) 2007 Elsevier Ireland Ltd. All fights reserved.

引用

页码：223 / 234

页数：12

共 146 条

[1] High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses [J].

Abd El-Rehim, DM ;

Ball, G ;

Pinder, SE ;

Rakha, E ;

Paish, C ;

Robertson, JFR ;

Macmillan, D ;

Blamey, RW ;

Ellis, IO .

INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (03) :340-350

[2]

Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0

[3] Identification of high risk breast-cancer patients by gene expression profiling [J].

Ahr, A ;

Karn, T ;

Solbach, C ;

Seiter, T ;

Strebhardt, K ;

Holtrich, U ;

Kaufmann, M .

LANCET, 2002, 359 (9301) :131-132

[4]

ALLRED DC, 1990, ARCH SURG-CHICAGO, V125, P107

[5]

Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61

[6] THE NEU ONCOGENE ENCODES AN EPIDERMAL GROWTH-FACTOR RECEPTOR-RELATED PROTEIN [J].

BARGMANN, CI ;

HUNG, MC ;

WEINBERG, RA .

NATURE, 1986, 319 (6050) :226-230

[7]

Baum M, 2002, LANCET, V359, P2131

[8] The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27 [J].

Bear, HD ;

Anderson, S ;

Brown, A ;

Smith, R ;

Mamounas, EP ;

Fisher, B ;

Margolese, R ;

Theoret, H ;

Soran, A ;

Wickerham, DL ;

Wolmark, N .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4165-4174

[9]

Beckmann MW, 1996, ONCOLOGY, V53, P441

[10] Effect of screening and adjuvant therapy on mortality from breast cancer [J].

Berry, DA ;

Cronin, KA ;

Plevritis, SK ;

Fryback, DG ;

Clarke, L ;

Zelen, M ;

Mandelblatt, JS ;

Yakovlev, AY ;

Habbema, JDF ;

Feuer, EJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (17) :1784-1792

← 1 2 3 4 5 6 7 8 9 10 →